Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135395 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00135395 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants.
The verdict
NCT00135395, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v. LPV/RTV) in HIV-1 infected subjects who have experienced their first virologic failure while receiving a NNRTI-containing HAART regimen.
Interventions
- DRUG Atazanavir+ritonavir
- DRUG Lopinavir+ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135395
The ClinicalTrials.gov registry entry for NCT00135395 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atazanavir+ritonavir is the first listed.
NCT00135395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135395 about?
NCT00135395 is a clinical study titled "A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen". The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v. LPV/RTV) in HIV-1 infected subjects who have experienced their first virologic failure while receiving a NNRTI-containing HAART regimen.
What is the current status of trial NCT00135395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2004-05. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00135395?
The interventions under investigation include: Atazanavir+ritonavir (DRUG), Lopinavir+ritonavir (DRUG).
Who is sponsoring clinical trial NCT00135395?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.